Varian Medical Systems Receives 510(k) Clearance for Fast and Accurate Acuros(TM) Radiotherapy Treatment Planning ...( CHARLOTTESVILLE Va. July ...),Health

CHARLOTTESVILLE, Va., July 21 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) today announced that it has received FDA 510(k) clearance for the Acuros(TM) capability offered initially in its brachytherapy treatment planning system. The Acuros clearance was awarded as part of the market-leading Eclipse(TM) treatment planning system.

BrachyVision(TM) Acuros, recently introduced at the American Brachytherapy Society meeting in Toronto, Canada, enables superior dose calculation at unmatched speed. The system enables clinicians to rapidly calculate patient dose with an extremely high level of accuracy*.

"BrachyVision Acuros calculation times tend to average between three and eight minutes depending on the applicator used," says Hosea Mitchell, head of Varian's brachytherapy business unit. "By comparison, the same calculations could take hours or days using the standard Monte Carlo method."

"Securing 510(k) clearance is an important milestone in making this exciting new planning system available to brachytherapy practitioners," adds Mitchell. "Acuros represents a major step forward in terms of accuracy with timeframes that were previously thought unimaginable. It will help clinicians make better decisions about dose to their patients and further their knowledge to make treatments more accurate."

Varian is working exclusively with Transpire Inc., developers of Acuros, to bring the benefits of this fast and precise calculation method to the radiation oncology field. In so doing, Varian becomes the only brachytherapy supplier with this capability in a commercially available product.

Varian Medical Systems, the world leader in radiotherapy, is currently working to integrate the Acuros module into its Eclipse product for extern
'/>"/>